Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistence of Long-COVID symptoms in a heterogenous prospective cohort.
Mariani C, Borgonovo F, Capetti AF, Oreni L, Cossu MV, Pellicciotta M, Armiento L, Bocchio S, Dedivitiis G, Lupo A, Galli M, Rizzardini G. Mariani C, et al. Among authors: dedivitiis g. J Infect. 2022 May;84(5):722-746. doi: 10.1016/j.jinf.2022.01.024. Epub 2022 Jan 22. J Infect. 2022. PMID: 35077770 Free PMC article. No abstract available.
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.
Capetti AF, Borgonovo F, Mileto D, Gagliardi G, Mariani C, Lupo A, Dedivitiis G, Meraviglia P, Pellicciotta M, Armiento L, Cossu MV, Rizzardini G. Capetti AF, et al. Among authors: dedivitiis g. J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.023. Epub 2021 May 27. J Infect. 2021. PMID: 34052240 Free PMC article.
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.
Borgonovo F, Stangalini CA, Tinelli C, Mariani C, Mileto D, Cossu MV, Abbati L, Bilardo L, Gagliardi G, Cutrera M, Pellicciotta M, Armiento L, Dedivitiis G, Capetti AF, Rizzardini G. Borgonovo F, et al. Among authors: dedivitiis g. Hum Vaccin Immunother. 2022 Nov 30;18(5):2060018. doi: 10.1080/21645515.2022.2060018. Epub 2022 May 5. Hum Vaccin Immunother. 2022. PMID: 35511791 Free PMC article.
Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.
Capetti AF, Stangalini CA, Borgonovo F, Mileto D, Oreni L, Dedivitiis G, Lupo A, Cossu MV, Bilardo L, Giacomelli A, Galli M, Rizzardini G. Capetti AF, et al. Among authors: dedivitiis g. Clin Infect Dis. 2021 Sep 15;73(6):e1402-e1403. doi: 10.1093/cid/ciab214. Clin Infect Dis. 2021. PMID: 33693610 Free PMC article. No abstract available.
cART durability and causes for treatment switching or discontinuation in HIV-positive patients older than 50 years of age.
Orlando G, Meraviglia P, Valsecchi L, Mainini A, Schiavini M, Merli S, Cordier L, Angeli E, Giorgi R, Atzori C, Dedivitiis G, Beretta R, Fasolo M, Zampini L, Gubertini G, Fasan M, Zambelli A, Gulisano C, Mazza F, Minisci D, Ricci E, Rizzardini G. Orlando G, et al. Among authors: dedivitiis g. J Acquir Immune Defic Syndr. 2010 Oct;55(2):e12-4. doi: 10.1097/QAI.0b013e3181ef791b. J Acquir Immune Defic Syndr. 2010. PMID: 20859084 No abstract available.
Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M, Scaglione G, Fassio F, Galli L, Lai A, Bergna A, Gabrieli A, Tarkowski M, Ventura CD, Colombo V, Cordier L, Bernasconi D, Corbellino M, Dedivitiis G, Borghetti S, Visigalli D, Sollima S, Casalini G, Rizzardini G, Gori A, Antinori S, Riva A, Schiavini M. Colaneri M, et al. Among authors: dedivitiis g. Virol J. 2024 Mar 20;21(1):68. doi: 10.1186/s12985-024-02333-x. Virol J. 2024. PMID: 38509536 Free PMC article.